E. Kreklau

发表

A novel fluorometric oligonucleotide assay to measure O( 6)-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase.

M. Kelley, M. Limp-Foster, L. Erickson, 2001, Nucleic acids research.

Small Molecule Therapeutics A Novel CDK 9 Inhibitor Shows Potent Antitumor Ef fi cacy in Preclinical Hematologic Tumor Models

R. Gaynor, Y. Qian, Jian Du, 2014 .

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

R. Gaynor, Y. Qian, Jian Du, 2014, Molecular Cancer Therapeutics.

In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations.

David A. Williams, K. Pollok, S. Ragg, 2003, Human gene therapy.

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Shobha N. Bhattachar, R. Campbell, Y. Qian, 2019, Molecular Cancer Therapeutics.

Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.

David A. Williams, K. Pollok, L. Erickson, 2003, Molecular cancer therapeutics.

Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity.

M. Berger, R. Pieper, Y. Hirose, 2003, Journal of neurosurgery.

Comparison of single- versus double-bolus treatments of O(6)-benzylguanine for depletion of O(6)-methylguanine DNA methyltransferase (MGMT) activity in vivo: development of a novel fluorometric oligonucleotide assay for measurement of MGMT activity.

K. Cornetta, L. Erickson, E. Kreklau, 2001, The Journal of pharmacology and experimental therapeutics.

Prolonged Inhibition ofO6-Methylguanine DNA Methyltransferase in Human Tumor Cells by O6-Benzylguanine In Vitro and In Vivo

L. Erickson, E. Kreklau, C. Kurpad, 1999 .

Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo.

D. Williams, L. Erickson, E. Kreklau, 1999, The Journal of pharmacology and experimental therapeutics.

Synthesis and preliminary biological evaluation of O6-[4-(2-[18F]fluoroethoxymethyl)benzyl]guanine as a novel potential PET probe for the DNA repair protein O6-alkylguanine-DNA alkyltransferase in cancer chemotherapy.

Q. Zheng, L. Erickson, Barbara J. Bailey, 2005, Bioorganic & medicinal chemistry.

O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma

S. Ma, J. Hansson, U. Ringborg, 2003, British Journal of Cancer.

In vivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human G-CSF-mobilized peripheral blood cells.

K. Pollok, R. Abonour, B. Juliar, 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

Modulation of 1,3-bis-(2-chloroethyl)-1-nitrosourea resistance in human tumor cells using hammerhead ribozymes designed to degrade O6-methylguanine DNA methyltransferase mRNA.

L. Erickson, E. Kreklau, Q. Zhang, 2001, The Journal of pharmacology and experimental therapeutics.

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

P. Iversen, L. Gelbert, Concha Sánchez-Martínez, 2014, Investigational New Drugs.

Abstract B233: Identification and characterization of LY2835219: A potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) with broad in vivo antitumor activity.

L. Gelbert, Concha Sánchez-Martínez, B. Neubauer, 2011 .

What is your diagnosis? CBC and cytogram data from a Sprague-Dawley rat.

E. Kreklau, A. R. Irizarry Rovira, 2012, Veterinary clinical pathology.

In Vitro L6 Irritation Assay Predicts Clinical Injection Site Reactions for Small Molecules.

T. K. Baker, J. Willy, Jennie L. Walgren, 2016, Toxicological sciences : an official journal of the Society of Toxicology.

A novel CDK9 inhibitor shows potent anti-tumor efficacy in preclinical hematological tumor models

R. Gaynor, X. Ye, J. J. Starling, 2014 .